eShowcase: GlobalView EventNet
System enables IRB members to review ?s in near real-time from anywhere in the world
System enables IRB members to review AEs in near real-time from anywhere in the world
GlobalView EventNet
PPD, Inc. (Wilmington, NC) just released a customizable, global event management and adjudication system for quick review of safety and endpoint-driven data from large clinical trials or registries. The secure, Internet-based system provides broad access to adverse event data, particularly in studies with multiple information sources and ones that need review by a board of independent physicians.
GlobalView EventNet provides access to data in near real-time and allows IRB members to examine the data at their own convenience from any location around the world. The board members can also request follow-up information or confirm adjudicated events through an online interface. GlobalView EventNet also sends automatic email alerts to prompt and encourage timely review. The system electronically compares each IRB member's decision and documents them per established guidelines.
PPD, Inc., (910) 251-0081, www.ppdi.com
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
